Title : Celecoxib With Neoadjuvant Chemotherapy for Breast Cancer Might Worsen Outcomes Differentially by COX-2 Expression and ER Status: Exploratory Analysis of the REMAGUS02 Trial.

Pub. Date : 2019 Mar 10

PMID : 30702971






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 COX-2 inhibitors should preferably be avoided during docetaxel use in patients with breast cancer who are undergoing NAC. Docetaxel prostaglandin-endoperoxide synthase 2 Homo sapiens